Syros Pharmaceuticals (NASDAQ:SYRS) Earns “Market Perform” Rating from JMP Securities

Syros Pharmaceuticals (NASDAQ:SYRS)‘s stock had its “market perform” rating reissued by JMP Securities in a research report issued on Wednesday,Benzinga reports.

A number of other analysts also recently issued reports on SYRS. HC Wainwright reissued a “neutral” rating and issued a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday. StockNews.com cut shares of Syros Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. TD Cowen reiterated a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday. Finally, Piper Sandler reissued an “overweight” rating and set a $5.00 target price (down from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Syros Pharmaceuticals has an average rating of “Hold” and an average target price of $3.33.

Syros Pharmaceuticals Price Performance

Shares of SYRS stock opened at $2.73 on Wednesday. The firm’s 50 day moving average price is $2.04 and its two-hundred day moving average price is $3.85. The stock has a market cap of $73.25 million, a PE ratio of -0.90 and a beta of 1.59. Syros Pharmaceuticals has a 52-week low of $1.43 and a 52-week high of $8.17. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.25 and a current ratio of 2.25.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($0.76) by $0.08. During the same quarter in the prior year, the firm earned ($1.35) earnings per share. As a group, analysts forecast that Syros Pharmaceuticals will post -2.94 EPS for the current year.

Insider Transactions at Syros Pharmaceuticals

In other Syros Pharmaceuticals news, CEO Conley Chee acquired 50,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were acquired at an average cost of $1.51 per share, with a total value of $75,500.00. Following the transaction, the chief executive officer now owns 72,504 shares of the company’s stock, valued at $109,481.04. The trade was a 200.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other Syros Pharmaceuticals news, CFO Jason Haas bought 45,344 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was acquired at an average price of $1.68 per share, for a total transaction of $76,177.92. Following the completion of the transaction, the chief financial officer now directly owns 124,552 shares of the company’s stock, valued at approximately $209,247.36. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Conley Chee purchased 50,000 shares of the firm’s stock in a transaction dated Tuesday, September 10th. The shares were bought at an average cost of $1.51 per share, with a total value of $75,500.00. Following the purchase, the chief executive officer now directly owns 72,504 shares of the company’s stock, valued at approximately $109,481.04. This represents a 200.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 130,707 shares of company stock valued at $206,491 in the last ninety days. 12.26% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

Large investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in shares of Syros Pharmaceuticals in the first quarter worth about $64,000. GSA Capital Partners LLP purchased a new stake in shares of Syros Pharmaceuticals in the 3rd quarter valued at approximately $34,000. Acadian Asset Management LLC purchased a new position in shares of Syros Pharmaceuticals during the 1st quarter worth approximately $91,000. Certuity LLC purchased a new position in Syros Pharmaceuticals in the 2nd quarter valued at approximately $109,000. Finally, Kennedy Capital Management LLC acquired a new stake in shares of Syros Pharmaceuticals in the 1st quarter valued at $2,166,000. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.